Wednesday, April 14, 2021 The MAC9 (S0307) PHASE III TRIAL OF BISPHOSPHONATES AS ADJUVANT THERAPY FOR PRIMARY BREAST CANCER trial has been permanently closed. PURPOSE: This randomized phase III trial studied zoledronate to see how well it works compared to clodronate or ibandronate in treating women who have undergone surgery for stage I, stage II, or stage III breast cancer. Primary Publication Gralow JR, Barlow WE, Paterson AHG, Miao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN Phase III randomized trial of bisphosphonates as adjuvant therapy in breast cancer: S0307 JNCI: Journal of the National Cancer Institute:112(7):698 -707,2020 Clinicaltrials.gov Results Reporting: NCT00127205: Study Results are available on www.clinicaltrials.gov The letter of termination has been posted on the trial page as well as the permanent closure webpage here: https://www.ctg.queensu.ca/trials/permanent_closure/permanent-trial-closure.
